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multiple courses of TACE is difficult to ascertain since additional courses may be 
prescribed under a patient-specific treatment protocol or due to non-optimal 
tumor response. Nonetheless, mean survival after discontinuing TACE was 
relatively similar regardless of number of treatments received.  
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CP1  
ADJUSTING FOR INFLATION IN ECONOMIC EVALUATIONS OF HEALTH 
TECHNOLOGIES: ARE WE DOING IT WRONG?  
Paulden M 
University of Toronto, Toronto, ON, Canada  
OBJECTIVES: Economic evaluations of health technologies typically require 
consideration of costs incurred in future years. Conventionally, all costs are 
represented in ‘real terms’ by adjusting for inflation. Future costs are then 
discounted to account for time preference. Although much has been written on 
the practice of discounting, health economists have paid surprisingly little 
attention to the issue of appropriately adjusting for inflation. This paper argues 
that the conventional approach to adjusting for inflation in economic 
evaluations of health technologies is inappropriate. METHODS & RESULTS: The 
conventional approach follows the recommendations of the Washington Panel: 
costs must be converted to “constant dollars” using a single inflation rate 
representing the rate of “general price inflation”. However, “if the prices of the 
goods in question change at a rate different from general price levels, this 
variation should be reflected in the adjustment used”. Some analyses therefore 
use the ‘Medical Component’ of the Consumer Price Index (CPI), or an equivalent 
measure, rather than the headline rate. Critically, for the conventional approach 
to be appropriate requires that all costs change at the same rate over time. This 
is generally not the case – some costs may rise (e.g. pharmaceuticals) at the same 
time as other costs fall (e.g. personal computers). In particular, products losing 
patent protection may experience a sudden fall in price out-of-line with general 
price inflation. A solution is to assign each cost a unique time profile subject to 
specific market conditions. Rather than applying an inflation rate, future costs 
are instead estimated using a unique projection model for each cost. 
CONCLUSIONS: The conventional approach to adjusting for inflation is 
inappropriate. A solution is to estimate a unique time profile for each cost 
component. Models routinely used by financial analysts may provide an example 
for how this projection can be done in practice.  
 
CP2  
THE NOTION OF REPRESENTATIVE LANGUAGES IN THE CONTEXT OF 
TRANSLATABILITY ASSESSMENT  
Basse SJ, Martin ML, McCarrier KP 
Health Research Associates, Inc., Seattle, WA, USA  
BACKGROUND: While current best-practices in PRO development include 
evaluation of the relative ease of translation for global trial use prior to 
instrument finalization, methodologies for this translatability assessment (TA) 
vary greatly. In the proposed approach, representative languages (RLs) are 
selected to assess the translation difficulty of PRO concepts without the time and 
cost of evaluating multiple languages with shared characteristics. METHODS: In 
the genealogical approach employed by linguists, languages sharing a common 
ancestor that become separated by geographical or socio-political boundaries 
will evolve in distinct ways, resulting in sets of languages (families) with 
common linguistic features (e.g. word order, phrasal structure, morphology, 
lexical items, etc.). Because of this relative similarity within language groups, 
efficiency can be gained by assessing translatability with sets of appropriately-
selected representative languages, which can in turn predict translation 
problems likely to affect others in their linguistic families. As such, use of 
appropriate criteria for the selection the RLs is of key importance. RESULTS: 
Selection of RLs should be based both on linguistic properties and other features 
salient to outcomes research. A family or group of languages may also be defined 
by shared characteristics that are not purely linguistic in nature. Features such 
as geographic and cultural (religious/dietary/social) aspects, number and 
distribution of speakers worldwide, and criteria related to health care utilization 
or study implementation should be considered in the definition of language 
families/groups and in the selection of RLs. CONCLUSIONS: Despite differences 
that undeniably exist between individual languages, limited information can be 
gained by the repetitive assessment of prospective translation difficulty within 
groups of languages having similar characteristics. Instead, the use of a 
representative language to assess translation difficulty for a related group of 
languages provides greater resource efficiency and more effective application of 
TA in providing important feedback prior to finalization of newly developed 
measures.  
 
CP3  
PIECEWISE MODELING OF TIME-TO-EVENT DATA WITH FLEXIBLE 
PARAMETERIZATION OF COVARIATES AND EFFECTS  
Ishak KJ 
United BioSource Corporation, Dorval, QC, Canada  
Projection of time-to-event distributions is necessary to obtain accurate 
estimation of life expectancy, or prediction of event times for economic models. 
Parametric survival analysis techniques are typically used, and can represent a 
broad range of shapes. In some cases, however, the best distributional fit fails to 
capture the variation in hazards over the entire time span, or it provides 
acceptable fit to the data but yields clinically implausible projections (e.g., 
constant hazard of death). More flexible techniques, like piecewise exponential 
models, can overcome these issues but remain generally underused. In 
piecewise models, the time axis is divided into contiguous segments with a 
common parametric distribution assumed within each segment, but values of 
the parameters are allowed to vary. In addition to greater flexibility, this 
framework allows inclusion of time-dependent predictors and/or time-
dependent effects. Two important considerations are the number and placement 
of divisions on the time axis, and the choice of the common distribution. 
Examination of the cumulative and log-cumulative hazards plots can assist with 
these issues. For instance, the number/placement of divisions for a piecewise-
exponential model could be determined visually such that the points within 
each division of the cumulative hazard plot follow a linear pattern. The same can 
be done with log-cumulative hazard function for a piecewise-Weibull model. 
Although piecewise-exponential models can be made progressively more flexible 
by increasing the number of segments to capture even very complex patterns, 
the assumption of a constant hazard for the last segment can be limiting for 
projection. Thus, models based on Weibull distributions may be more 
appropriate, and possibly achieve similar fit with fewer segments. The 
subjectivity involved in these decisions can be minimized by using numeric 
optimizing strategies (e.g., grid search for placement of divisions) and use of fit 
statistics to select distributions.  
 
CP4  
MEASURING HEALTH OUTCOMES IN THE ABSENCE OF RIGOUR: WILLFUL 
IGNORANCE OR DELIBERATE MALPRACTICE?  
Kind P 
University of Leeds, Leeds, UK  
The evaluation of cost-effectiveness plays a central role in appraisal of new 
technologies undertaken by regulatory agencies across the world. As a 
consequence, health economists now play a critical part in generating the 
evidence base used to determine both access to and the price of treatment. No 
matter the complexity of any economic evaluation there is an inescapable need 
to describe and value the benefits of health care interventions. The computation 
of an ICER depends totally on the capacity to quantify marginal changes in 
health status. The orthodoxy adopted by most HTA agencies relies on the notion 
of capturing such outcomes via the use of generic health status measurement 
systems (for example HUI or EQ-5D) together with their corresponding social 
preference weights. The requirement that the values of the general population 
constitute the “correct” perspective is one element of the health economics 
credo. A second dictates that the “worth” of a health outcome shall be expressed 
in terms of utility – a concept that lacks a defined unit of measure or any agreed 
standard elicitation method. It is a regrettable fact that although health 
economists privately recognise the non-commensurability of Standard Gamble 
(SG) and Time Trade-Off (TTO) methods their public posture generally belies this 
contradiction. The status of the QALY as a useful metric of health benefit/loss 
has been fatally compromised by the failure of the scientific community to agree 
on a single method for determining the quality-adjustment factor. The 
preparedness of health economists to ignore this gap in their armamentarium 
runs counter to the rational practice of science. This paper challenges the 
intellectual deadweight of traditional health economics, specifically in regards to 
the measurement of health outcomes. Examples of defective practice drawn 
from Canadian and UK HTA reports will be used to illustrate the conceptual 
issues raised in this paper.  
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HC1  
ORPHAN DISEASE DRUG COSTS IN THE UNITED STATES: ASSESSMENT OF 
LAUNCH PRICING TRENDS IN NON-CANCER ORPHAN DISEASES AND THE 
FUTURE IMPLICATIONS ON HEALTH SYSTEM ACCESS  
Davis EA1, Schwartz EL2 
1Metabolic Markets LLC, San Clemente, CA, USA, 2PriceSpective LLC, San Diego, CA, USA  
OBJECTIVES: With an increasing number of orphan disease (OD) drugs in 
development, the objective of the current study is to assess launch pricing trends 
of orphan drugs in the U.S. From this pricing assessment, implications and 
effects of increasing orphan drug prices on US managed care payer access is 
discussed. METHODS: Non-cancer OD approvals between 2003 and 2012 were 
extracted from the FDA Orphan Products database. Oncology and acute 
indications were excluded due to the confounders of acute and chronic 
treatments. Wholesale acquisition cost drug prices were collected from 
Medispan-PriceRx for product launch year. Annualized drug costs were 
calculated using the product label and consistent assumptions on weight-based 
dosing. Drug costs were adjusted to 2012 dollars using the CPI. RESULTS: From 
2003-2012, 33 ODs gaining U.S. market approval were included in the present 
analysis, with 30% of the drugs approved in 2011 and 2012. Launch pricing trends 
indicate that average launch price of ODs has increased 107% to $276,471/year 
during the examined time period. In 2012, 4 of 6 new ODs were priced between 
$294,000 and $295,000. CONCLUSIONS: The OD approvals and prices have grown 
substantially since 2003, accelerating in the last two years. The historically open 
US payer policy towards ODs must be reconsidered for sustainability. Expansion 
of the covered population will increase the traditionally modest payer OD 
economic burden, accelerated by new treatments. Payers must prepare by 
creating OD policy that identifies the most appropriate patients through 
collaboration with thought leaders and manufacturers. Payer investment should 
be made in patient management programs to ensure clinical benefit is delivered. 
The OD regulatory mechanism encourages manufacturers to invest modestly in 
clinical development and assign ultra-premium prices. Manufacturers may be 
